A recent study has shown that glibenclamide, by targeting the K+ channel, modulates the expression of p70S6K and KLF4 in non-small cell lung cancer, and exerts an anticancer effect in both in vitro as well as in in vivo models [47]. The gene discussed is RPS6KB1; the disease is non-small cell lung carcinoma.